source
- Rapport Therapeutics reports Phase 2 success for J&J-licensed bipolar mania drugRapport Therapeutics announced that its oral investigational drug, which modulates AMPA receptors, has successfully completed a Phase 2 trial in patients with bipolar mania. The study met its prim…
- FDA issues final guidance on developing and labeling prescription drug appsThe FDA released its final guidance on Tuesday, outlining how drug sponsors should create, distribute, and label software applications that are used together with prescription medicines. The guida…